Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
MODERNA, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 77.70 USD | -1.66% | -0.60% | -56.74% | |
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2023-12-07
- Investor Day - ESG
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
77.70USD
Average target price
139.90USD
Spread / Average Target
+80.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.74% | 30 125 M $ | |
| +65.91% | 40 283 M $ | |
| +4.50% | 39 020 M $ | |
| -25.31% | 28 999 M $ | |
| +37.42% | 21 980 M $ | |
| -29.20% | 20 582 M $ | |
| +1.50% | 17 372 M $ | |
| -13.70% | 10 906 M $ | |
| -9.55% | 10 111 M $ | |
| -24.11% | 9 982 M $ |
- Stock
- Equities
- Stock Moderna, Inc. - Nasdaq
- News Moderna, Inc.
- EU, Moderna Said in Talks for New Supply Deal for COVID-19 Jab
